Quote:

---

Indeed if LL suppresses PDL1 in cancer cells completely then no need for Opdivo.

But that possibility is so ridiculous, so preposterous, so improbable that it hardly makes sense to consider.

---

Maraviroc reduces PD-L1 expression on tumor cells to lower than on non-tumor cells. Now consider that leronlimab has better receptor occupancy than maraviroc.

Quote:

---

No one has ever suggested LL could combo, let alone replace, Opdivo.

---

In 2019 on this board I said Keytruda (PD-1 inhibitor) was unnecessary because leronlimab downregulated PD-L1. Which was even before that article was published.